参麦注射液联合FOLFOX方案化疗治疗进展期胃癌近期疗效及对患者免疫功能和肿瘤标志物的影响  

Short-term efficacy of Shenmai injection combined with FOLFOX chemotherapy in the treatment of advanced gastric cancer and its effects on immune function and tumor markers

作　　者：张国平[1] 李攀 费浙钧 周麟 Zhang Guoping;Li Pan;Fei Zhejun;Zhou Lin(Second Department of Surgery,Shengzhou Hospital of Traditional Chinese Medicine,Shengzhou 312400,Zhejiang Province,China)

机构地区：[1]嵊州市中医院外二科,浙江省312400

出　　处：《中国基层医药》2021年第12期1839-1843,共5页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省医学会临床科研基金项目(第二批)(2019ZYC-A164)。

摘　　要：目的探讨参麦注射液联合FOLFOX方案化疗治疗进展期胃癌近期疗效及对患者免疫功能和肿瘤标志物的影响。方法选取嵊州市中医院2018年6月至2020年6月收治的进展期胃癌患者82例为观察对象,采用随机数字表法分为观察组与对照组,每组41例。对照组患者行FOLFOX方案化疗,观察组在FOLFOX方案基础上结合参麦注射液治疗。两组均以21 d为1个疗程,连续治疗3个疗程。比较两组化疗后近期疗效和生存质量改善情况;治疗前和治疗3个疗程免疫功能和肿瘤标志物[癌胚抗原(CEA)和糖类抗原724(CA724)]及不良反应发生情况。结果观察组总有效率[70.73%(29/41)]高于对照组[46.34%(19/41)],差异有统计学意义(χ^(2)=5.025,P<0.05)。观察组生存质量提高率[78.05%(32/41)]高于对照组[56.10%(23/41)],差异有统计学意义(χ^(2)=4.473,P<0.05)。观察组治疗3个疗程进展期胃癌患者CD3+[(58.39±3.14)%]、CD4+[(38.79±2.35)%]和CD4+/CD8+[(1.54±0.17)]均高于对照组[(48.10±3.01)%、(30.10±1.78)%、(0.92±0.15)],差异均有统计学意义(t=15.148、18.875、17.511,均P<0.05)。观察组治疗3个疗程进展期胃癌患者血清CEA[(6.98±1.45)μg/L]和CA724[(7.85±1.76)μg/L]均低于对照组[(15.47±3.21)μg/L、(18.97±3.25)μg/L],差异均有统计学意义(t=15.434、19.265,均P<0.05)。两组不良反应发生情况差异无统计学意义(P>0.05)。结论参麦注射液联合FOLFOX方案化疗治疗进展期胃癌近期疗效良好,且可提高患者免疫功能,降低CEA和CA724水平。Objective To investigate the short-term efficacy of Shenmai injection combined with FOLFOX chemotherapy in the treatment of advanced gastric cancer and its effects on immune function and tumor markers.Methods Eighty-two patients with advanced gastric cancer who received treatment in Shengzhou Hospital of Traditional Chinese Medicine,China between June 2018 and June 2020 were included in this study.They were randomly assigned to receive either FOLFOX chemotherapy(control group,n=41)or Shenmai injection combined with FOLFOX chemotherapy(observation group,n=41).All patients received three 21-day courses of treatment.Short-term efficacy of chemotherapy and improvement in quality of life were compared between the two groups.Immune function,expression of tumor markers(carcinoembryonic antigen and carbohydrate antigen 724)and adverse reactions were determined before and after three courses of treatment.Results Total effective rate in the observation group was significantly higher than that in the control group[70.73%(29/41)vs.46.34%(19/41),χ^(2)=5.025,P<0.05].The proportion of patients had improved quality of life in the observation group was significantly higher than that in the control group[78.05%(32/41)vs.56.10%(23/41),χ^(2)=4.473,P<0.05].After three courses of treatment,the proportion of CD3+and CD4+cells and the ratio of CD4+/CD8+cells in the observation group were(58.39±3.14)%,(38.79±2.35)%and(1.54±0.17),respectively,which were significantly higher than those in the control group[(48.10±3.01)%,(30.10±1.78)%,(0.92±0.15),t=15.148,18.875,17.511,all P<0.05].After three courses of treatment,serum carcinoembryonic antigen and carbohydrate antigen 724 levels in the observation group were(6.98±1.45)μg/L and(7.85±1.76)μg/L,respectively,which were significantly lower than those in the control group[(15.47±3.21)μg/L,(18.97±3.25)μg/L),t=15.434,19.265,both P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Shenmai injection combined with

关 键 词：胃肿瘤 抗肿瘤联合化疗方案 中草药提取物 药物疗法 联合 肿瘤标记 生物学 免疫调节 药物不良反应 生活质量 治疗结果 

分 类 号：R735.2[医药卫生—肿瘤]